Geschäft · 27.10.20261 Min. Lesezeit
Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience Pipeline
Lokale automatische Übersetzung · Originalsprache der Quelle
Zusammenfassung
Teva acquires worldwide rights to BXCL501, expanding its neuroscience pipeline with a potential at-home treatment for agitation currently under FDA review